IMGN ImmunoGen, Inc.

2.330.06 (+2.64%)
IEX real time price: 12:37:33 PM

Quote

Previous Close
$2.27
Day Range
$2.23-$2.37
52 Week Range
$1.76-$10.39
Volume
1,098,315
Avg Volume
3,495,686
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$348.41M
Enterprise Value (EV)
$227.47M
PE Ratio
-
EV/EBITDA
-1.51
Price/Sales
-
Price/Book
30.94
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$150.34M
EPS, ttm
-$1.20
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/2/2019 (15 days)
Debt to Equity
1,370%
Debt
$141.32M
Cash
$262.25M
Net Debt
-

Performance

Beta
1.86
200 Day Moving Avg
$4.17
50 Day Moving Avg
$2.23
52 Week Change
-77.44%
YTD Change
-49.87%
1 Month Change
5.58%
3 Month Change
-7.72%
6 Month Change
-55.49%
1 Year Change
-77.44%
2 Year Change
-12.23%
5 Year Change
-71.33%

Share Count

Shares Outstanding
149.5M
Float
-
Restricted Shares
149.5M
Restricted Shares, %
100.00%

ImmunoGen, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Mark J. Enyedy

Website: http://www.immunogen.com

Description: ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

Employees: 296